Abstract
Objectives Recent advancements have extended the treatment window for large vessel occlusion in acute ischemic stroke, prompting a shift in the standard of care for patients presenting within 6 to 24 hours. We developed and externally validated an automated deep learning algorithm for detecting thrombectomy amenable vessel occlusion (TAVO) in computed tomography angiography (CTA).
Methods The algorithm was trained on 2,045 acute ischemic stroke patients who underwent CTA, and validation was conducted using two external datasets comprising 64 (external 1) and 313 (external 2) patients with ischemic stroke. TAVO was defined as occlusion in the intracranial internal carotid artery (ICA), or M1/M2 segment of the middle cerebral artery (MCA). Utilizing U-Net for vessel segmentation and EfficientNetV2 for TAVO prediction, the algorithm’s diagnostic performance was assessed using the area under the receiver operating characteristics curve (AUC), sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV).
Results The mean age in the training and validation dataset was 68.7±12.6; 56.3% were men, and 18.0% had TAVO. The algorithm achieved AUC of 0.950 (95% CI, 0.915–0.971) in the internal test. For the external datasets 1 and 2, the AUCs were 0.970 (0.897–0.997) and 0.971 (0.924–0.990), respectively. Notably, the algorithm demonstrated robust sensitivity and specificity (approximately 0.95) for intracranial ICA or M1-MCA occlusion, but a slight reduction in performance for isolated M2-MCA occlusion.
Conclusion This validated algorithm has potential applications in identifying TAVO and could aid less-experienced clinicians, potentially expediting the treatment process for eligible patients.
Competing Interest Statement
Hoyeon Lee, Gi-Hoon Park, Hotak Hong, Dongmin Kim, and Wi-Sun Ryu are employee of JLK Inc.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study procedure was approved by the institutional review boards of Korea University Guro Hospital (2023GR280), and written consent was waived due to the retrospective and anonymized nature of the study design.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.